{"entity":{"id":"nct05394103","kind":"trial","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in metastatic cancer, run by Qurient Co., Ltd., now recruiting.","summary":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05394103 by Qurient Co., Ltd., with 130 participants planned, started 2022-08-30 and due to reach its primary completion in 2025-12-30. Interventions recorded: Q901, KEYTRUDA® (pembrolizumab). Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05394103","url":"https://clinicaltrials.gov/study/NCT05394103"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05394103","phase":"1/2","setting":"A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose","sponsor":"Qurient Co., Ltd.","enrolled":130,"outcomes":[]},"route":"/trials/nct05394103/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}